Nuclear magnetic resonance
In October 2014, Labcorp announced it had entered into an agreement to acquire [[Covance Inc.]] for approximately $6.1 billion. Just a few weeks later, Labcorp completed its $85.3 million acquisition of "LipoScience", a developer of diagnostic tests based on [[Nuclear magnetic resonance spectroscopy|nuclear magnetic resonance technology]] measuring heart disease risk.